NASDAQ:MTEX

Mannatech Competitors

$18.34

-0.18 (-0.97 %)

(As of 03/4/2021 04:30 PM ET)

Add

Compare

Today's Range

$18.10

Now: $18.34▼

$18.46

50-Day Range

$17.75

MA: $18.39▼

$19.21

52-Week Range

$6.49

Now: $18.34▼

$20.32

Volume1,428 shs

Average Volume2,403 shs

Market Capitalization$38.29 million

P/E Ratio5.64

Dividend Yield3.46%

Beta1.09

Mannatech (NASDAQ:MTEX) Vs. CGC, APHA, TLRY, CRON, USNA, and ACB

Should you be buying MTEX stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Mannatech, including Canopy Growth (CGC), Aphria (APHA), Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Mannatech vs. Canopy Growth Stock

Mannatech (NASDAQ:MTEX) and Canopy Growth (NASDAQ:CGC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Canopy Growth's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A
Canopy Growth	$297.34 million	39.20	$-993,370,000.00	$1.32	23.49

Mannatech has higher earnings, but lower revenue than Canopy Growth.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Canopy Growth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	0	0	0	0	N/A
Canopy Growth	5	10	4	1	2.05

Canopy Growth has a consensus target price of $38.5667, suggesting a potential upside of 24.37%. Given Canopy Growth's higher probable upside, analysts plainly believe Canopy Growth is more favorable than Mannatech.

Profitability

This table compares Mannatech and Canopy Growth's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	5.04%	28.69%	11.99%
Canopy Growth	-312.84%	-13.11%	-9.66%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 10.2% of Canopy Growth shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 0.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Canopy Growth on 7 of the 13 factors compared between the two stocks.

Mannatech vs. Aphria Stock

Mannatech (NASDAQ:MTEX) and Aphria (NASDAQ:APHA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Aphria's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A
Aphria	$405.96 million	13.04	$-63,210,000.00	($0.06)	-278.50

Mannatech has higher earnings, but lower revenue than Aphria.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Aphria has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Aphria, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	0	0	0	0	N/A
Aphria	0	3	6	0	2.67

Aphria has a consensus target price of $17.7857, suggesting a potential upside of 4.01%. Given Aphria's higher probable upside, analysts plainly believe Aphria is more favorable than Mannatech.

Profitability

This table compares Mannatech and Aphria's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	5.04%	28.69%	11.99%
Aphria	-36.10%	-2.30%	-1.66%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 10.3% of Aphria shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Aphria on 7 of the 12 factors compared between the two stocks.

Mannatech vs. Tilray Stock

Mannatech (NASDAQ:MTEX) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Tilray's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A
Tilray	$166.98 million	23.30	$-321,170,000.00	($1.69)	-13.40

Mannatech has higher earnings, but lower revenue than Tilray.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Tilray, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	0	0	0	0	N/A
Tilray	2	10	0	0	1.83

Tilray has a consensus target price of $18.3078, suggesting a potential downside of 19.63%. Given Tilray's higher probable upside, analysts plainly believe Tilray is more favorable than Mannatech.

Profitability

This table compares Mannatech and Tilray's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	5.04%	28.69%	11.99%
Tilray	-242.60%	-92.70%	-20.70%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 12.6% of Tilray shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mannatech beats Tilray on 7 of the 11 factors compared between the two stocks.

Mannatech vs. Cronos Group Stock

Mannatech (NASDAQ:MTEX) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

This table compares Mannatech and Cronos Group's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A
Cronos Group	$25.64 million	135.45	$1.17 billion	$0.67	14.39

Cronos Group has lower revenue, but higher earnings than Mannatech.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and Cronos Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	0	0	0	0	N/A
Cronos Group	2	5	2	0	2.00

Cronos Group has a consensus target price of $8.8333, suggesting a potential downside of 8.37%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Mannatech.

Profitability

This table compares Mannatech and Cronos Group's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	5.04%	28.69%	11.99%
Cronos Group	266.31%	-1.61%	-1.41%

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 11.8% of Cronos Group shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cronos Group beats Mannatech on 7 of the 12 factors compared between the two stocks.

Mannatech vs. USANA Health Sciences Stock

Mannatech (NASDAQ:MTEX) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Mannatech and USANA Health Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	0	0	0	0	N/A
USANA Health Sciences	0	0	2	0	3.00

USANA Health Sciences has a consensus target price of $126.00, suggesting a potential upside of 25.92%. Given USANA Health Sciences' higher probable upside, analysts plainly believe USANA Health Sciences is more favorable than Mannatech.

Risk & Volatility

Mannatech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Mannatech and USANA Health Sciences' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A
USANA Health Sciences	$1.06 billion	1.99	$100.53 million	$4.41	22.71

USANA Health Sciences has higher revenue and earnings than Mannatech.

Insider & Institutional Ownership

15.0% of Mannatech shares are owned by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are owned by institutional investors. 45.8% of Mannatech shares are owned by insiders. Comparatively, 45.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Mannatech and USANA Health Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	5.04%	28.69%	11.99%
USANA Health Sciences	10.57%	32.91%	22.26%

Summary

USANA Health Sciences beats Mannatech on 10 of the 12 factors compared between the two stocks.

Mannatech vs. Aurora Cannabis Stock

Aurora Cannabis (NYSE:ACB) and Mannatech (NASDAQ:MTEX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, meaning that its stock price is 244% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 15.0% of Mannatech shares are held by institutional investors. 45.8% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aurora Cannabis and Mannatech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-1,238.94%	-16.32%	-13.12%
Mannatech	5.04%	28.69%	11.99%

Earnings and Valuation

This table compares Aurora Cannabis and Mannatech's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$207.89 million	9.32	$-2,468,190,000.00	($2.86)	-3.43
Mannatech	$157.73 million	0.24	$3.29 million	N/A	N/A

Mannatech has lower revenue, but higher earnings than Aurora Cannabis.

Analyst Ratings

This is a breakdown of current ratings and price targets for Aurora Cannabis and Mannatech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	6	9	0	0	1.60
Mannatech	0	0	0	0	N/A

Aurora Cannabis presently has a consensus price target of $11.2445, suggesting a potential upside of 14.62%. Given Aurora Cannabis' higher possible upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Mannatech.

Summary

Mannatech beats Aurora Cannabis on 7 of the 11 factors compared between the two stocks.